These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34064473)

  • 21. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
    Span PN; Tjan-Heijnen VC; Heuvel JJ; de Kok JB; Foekens JA; Sweep FC
    Clin Chem; 2006 Sep; 52(9):1693-700. PubMed ID: 16873289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma.
    Troiano G; Guida A; Aquino G; Botti G; Losito NS; Papagerakis S; Pedicillo MC; Ionna F; Longo F; Cantile M; Pennella A; Lo Russo L; Di Gioia G; Mariggiò MA; Lo Muzio L; Pannone G
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a nine-lncRNA signature as a novel prognostic marker of estrogen receptor-negative breast cancer.
    Wang Z; Wang J; Liu L; He Q; Wei M
    Oncol Lett; 2020 Apr; 19(4):2979-2988. PubMed ID: 32218854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer.
    Reynisdottir I; Arason A; Freysteinsdottir ES; Kristjansdottir SB; Hilmarsdottir B; Traustadottir GA; Johannsson OT; Agnarsson BA; Barkardottir RB
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells.
    Zhao G; Wang Q; Gu Q; Qiang W; Wei JJ; Dong P; Watari H; Li W; Yue J
    Oncotarget; 2017 Nov; 8(55):94666-94680. PubMed ID: 29212257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
    Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
    Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
    Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
    Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between functional variants in BIRC5/survivin gene 3' untranslated region and mRNA expression in lymphoblastoid cell lines.
    Pu F; Shao Z; Yang S; Liu J; Lin S; Ma X; Yang H
    Oncol Lett; 2015 Oct; 10(4):2319-2322. PubMed ID: 26622842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
    Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
    Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.
    Hu Z; Huang G; Sadanandam A; Gu S; Lenburg ME; Pai M; Bayani N; Blakely EA; Gray JW; Mao JH
    Breast Cancer Res; 2010; 12(2):R18. PubMed ID: 20211017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of cell free BIRC5 mRNA as a serum diagnostic and prognostic biomarker for colorectal cancer.
    Wang H; Zhang X; Wang L; Zheng G; Du L; Yang Y; Dong Z; Liu Y; Qu A; Wang C
    J Surg Oncol; 2014 May; 109(6):574-9. PubMed ID: 24338523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer.
    Yakirevich E; Samkari A; Holloway MP; Lu S; Singh K; Yu J; Fenton MA; Altura RA
    Hum Pathol; 2012 Jun; 43(6):865-73. PubMed ID: 22055399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical value of survivin and its underlying mechanism in ovarian cancer: A bioinformatics study based on GEO and TCGA data mining.
    Li XJ; Pang JS; Li YM; Ahmed FA; He RQ; Ma J; Ma FC; Chen G
    Pathol Res Pract; 2018 Mar; 214(3):385-401. PubMed ID: 29499854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BIRC5 Genomic Copy Number Variation in Early-Onset Breast Cancer.
    Ghaffari K; Hashemi M; Ebrahimi E; Shirkoohi R
    Iran Biomed J; 2016 Sep; 20(4):241-5. PubMed ID: 27372966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker.
    Mirza Z
    Curr Med Chem; 2024; 31(5):649-663. PubMed ID: 37194228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
    Hinnis AR; Luckett JC; Walker RA
    Br J Cancer; 2007 Feb; 96(4):639-45. PubMed ID: 17285125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
    Joseph C; Alsaleem M; Orah N; Narasimha PL; Miligy IM; Kurozumi S; Ellis IO; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jul; 182(2):267-282. PubMed ID: 32445177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.